dc.contributor.author
Busse, David
dc.contributor.author
Schaeftlein, André
dc.contributor.author
Solms, Alexander
dc.contributor.author
Ilia, Luis
dc.contributor.author
Michelet, Robin
dc.contributor.author
Zeitlinger, Markus
dc.contributor.author
Huisinga, Wilhelm
dc.contributor.author
Kloft, Charlotte
dc.date.accessioned
2021-04-16T14:20:51Z
dc.date.available
2021-04-16T14:20:51Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/30405
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-30146
dc.description.abstract
Purpose
Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response.
Methods
39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches.
Results
Individual AUCISF estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%–143%CVPK, integral-CA = 26.4%–72.6%CVPK) from recovery-related variability only in integral-CA (41.0%–50.3%CVrecovery). This also led to increased variability of AUCplasma for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values.
Conclusions
Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making.
en
dc.format.extent
15 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
levofloxacin
en
dc.subject
microdialysis
en
dc.subject
noncompartmental analysis
en
dc.subject
nonlinear mixed-effects modelling
en
dc.subject
probability of target-attainment
en
dc.subject.ddc
500 Naturwissenschaften und Mathematik::540 Chemie::540 Chemie und zugeordnete Wissenschaften
dc.title
Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s11095-021-02994-1
dcterms.bibliographicCitation.journaltitle
Pharmaceutical Research
dcterms.bibliographicCitation.number
3
dcterms.bibliographicCitation.pagestart
381
dcterms.bibliographicCitation.pageend
395
dcterms.bibliographicCitation.volume
38
dcterms.bibliographicCitation.url
https://doi.org/10.1007/s11095-021-02994-1
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie
refubium.funding
Springer Nature DEAL
refubium.note.author
Die Publikation wurde aus Open Access Publikationsgeldern der Freien Universität Berlin gefördert.
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.issn
0724-8741
dcterms.isPartOf.eissn
1573-904X